Many researchers are attempting to identify drugs that can be repurposed as effective
therapies for Alzheimer's disease (AD). Several recent studies have highlighted epidermal …

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder in the
world. Motor impairment seen in PD is associated with dopaminergic neurotoxicity in the …

The coronavirus disease 2019 (COVID-19) pandemic has caused over 600,000,000
infections globally thus far. Up to 30% of individuals with mild to severe disease develop …

Parkinson's disease (PD) is characterized by motor impairments and progressive
dopaminergic neuronal death in the substantia nigra (SN). Recently, the involvement of …

Alzheimer's Disease (AD) is a disorder characterized by cognitive decline,
neurodegeneration, and accumulation of amyloid plaques and tau neurofibrillary tangles in …

Background Recently, single-nucleus RNA-seq (snRNA-seq) analyses have revealed
important cellular and functional features of Alzheimer's disease (AD), a prevalent …

Gene expression quantitative trait loci are widely used to infer relationships between genes
and central nervous system (CNS) phenotypes; however, the effect of brain disease on …

Background Acanthopanax senticosus (AS) can improve sleep, enhance memory, and
reduce fatigue and is considered as an effective drug for Alzheimer's disease (AD). The …

Tideglusib is a non-competitive GSK-3β inhibitor which contain 1, 2, 4-thiadiazolidine-3, 5-
dione moiety, and now mainly used for progressive supranuclear palsy due to the lack of …

There are approximately 24 million cases of Alzheimer's disease (AD) worldwide, and the
number of cases is expected to increase four-fold by 2050. AD is a neurodegenerative …